$LCTX News
Last published 1w ago
- 1w agoLCTXLineage Provides Update on ReSonance® Program for Hearing LossBusiness WireAdvanced Collaboration with WDI for ReSonance (ANP1) Program Into Second Year: All Preclinical Development Activities Planned For Year 1 of Collaboration Successfully AchievedDanish Medicines Agency (DKMA) Meeting
- 2mo agoLCTXLineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing PlatformBusiness WireU.S. Patent No. 12,692,476 Has an Expected Expiration Date of June 9, 2043 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off
- 3mo agoLCTXLineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness WirePositive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program
- 3mo agoLCTXLineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today
- 4mo agoLCTXLineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial DiseaseBusiness WireCompany Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the
- 4mo agoLCTXLineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare SummitBusiness WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that
- 5mo agoGERNBIOALCTXFATECell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsPR NewswireMarket News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move...
- 6mo agoLCTXLineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateBusiness WirePositive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with
- 6mo agoLCTXLineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that it will
- 6mo agoLCTXOpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026Business WireGains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site OCT imaging indicated partial
- 7mo agoLCTXLineage Announces Formation of Scientific Advisory BoardBusiness WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the
- 7mo agoLCTXOCGNVRTXLGVNBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsPR NewswireFor most of modern biology, aging has been treated as a backdrop — the inevitable canvas on which individual diseases are painted. That is beginning...
- 7mo agoVCELSANALCTXELDNWhy Smart Money Is Shifting From Clinical Data to Manufacturing LinesPR NewswireThe global cell therapy manufacturing market is on track to nearly double, from $7.17 billion in 2026 to over $14 billion by 2035[1]. The science has ...
- 7mo agoLCTXLineage Launches New Cell Therapy Program in Corneal Endothelial DiseaseBusiness WireNew Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted
- 7mo agoMESOLGVNLCTXMNKDA Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.PR NewswireEquity-Insider.com — There is a key "master" protein in your body called α-Klotho. You've probably never heard of it. But the scientific community...
- 8mo agoLCTXLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateBusiness WirePositive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on
- 8mo agoLCTXLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it
- 9mo agoMNKDALTLCTXARWRLongevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationPR NewswireUSA News Group News Commentary – Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27 trillion...
- 11mo agoPROKMESOLCTXBeyond Insulin Pumps: Cell Therapies Unlock a $403B Cure EconomyPR NewswireThe cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations...
- 1y agoLCTXLineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness WirePositive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for
- 1y agoLCTXLineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it
- 1y agoLCTXLineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks TranscriptEarnings Call Transcripts
- 1y agoLCTXLineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 DiabetesBusiness WireInitial Program Focus Will Be On Addressing Manufacturing Scale Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf",
- 1y agoLCTXLineage Cell Therapeutics to Present at September 2025 Investor ConferencesBusiness WireH.C. Wainwright 27th Annual Global Investment Conference Presentation on September 8, 2025 Baird's 2025 Global Healthcare Conference Presentation on September 9, 2025 Lineage Cell Therapeutics, Inc. (NYSE
- 1y agoLCTXLineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing LossBusiness WireThree-year term intended to advance preclinical development of ReSonance Up to $12 million of development costs to be contributed by William Demant Invest Lineage Cell Therapeutics, Inc. (NYSE American and TASE:
- 1y agoLCTXLineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoLCTXLineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness WirePositive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP
- 1y agoLCTXLineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its
- 1y agoLCTXLineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord InjuryBusiness WireSuccessful First-In-Human Use of New Parenchymal Spinal Delivery System First-ever Administration of OPC1 to a Chronic Injury Patient Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a
- 1y agoLCTXOpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025Business WireMean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion site Evidence of retinal structural improvement persisted out to 3
- 1y agoLCTXLineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor SymposiumBusiness WireFully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies
- 1y agoLCTXLineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCBusiness WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief
- 1y agoLCTXRG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from
- 1y agoLCTXLineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its
- 1y agoLCTXLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor SymposiumBusiness WireFully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and
- 1y agoLCTXLineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)Business WireLineage Participating in Panel Discussion of Novel Retina Drug Delivery Approaches at Eyecelerator@ Park City 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company
- 1y agoLCTXLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateBusiness WirePositive 24 Month Visual Acuity Data with OpRegen® in Geographic Atrophy Patients Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit Signed Services Agreement with Genentech to Further Support
- 1y agoLCTXLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its
- 1y agoLCTXLineage Initiates Clinical Study of OPC1 for Spinal Cord InjuryBusiness WireSafety Study of Stem Cell-derived Transplant Includes Subacute and Chronic SCI Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell
- 1y agoLCTXLineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences ConferenceBusiness WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley,
- 1y agoLCTXLineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct OfferingBusiness WireLineage Has Now Received $30 Million in Gross Proceeds and May Receive an Additional $36 Million in Gross Proceeds Upon the Full Exercise of OpRegen® Clinical Milestone-linked Warrants Lineage Cell Therapeutics,
- 1y agoLCTXLineage Cell Therapeutics Issues Letter to StockholdersBusiness WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting
- 1y agoLCTXLineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct OfferingBusiness Wire$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE:
- 1y agoLCTXLineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct OfferingBusiness Wire$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE:
- 1y agoLCTXLineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoLCTXLineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness WireOpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell
- 2y agoLCTXLineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024Business WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter
- 2y agoLCTXLineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare SummitBusiness WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief
- 2y agoLCTXOpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International SymposiumBusiness WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief
- 2y agoLCTXLineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology WorkshopBusiness WireReSonance is Manufactured by a Proprietary Process, Developed In-House, at Clinical Scale, with Relevant In-Vitro Functional Activity Immediate-Use, Thaw-and-Inject Formulation Durably Engrafted in Multiple